Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Oct 10, 2014 5:52pm
391 Views
Post# 23020472

Company = Responsive. EOM. "Commenced" = Great News. EOM.

Company = Responsive. EOM. "Commenced" = Great News. EOM.Seems that some people have an agenda.  Thus, I'll share my experience in contacting the company this week....

After the presentation by Don on Monday regarding RVX, I had a question about that famous last line in the presentation.  I wanted to know what was meant by discussions having "commenced."  Specifically, the presentation mentioned that those discussions were for business development, licensing and partnerships.

Since we have known for years that "discussions" have been underway at various times, I basically wanted to know what changed and what was meant by that curious phrase - a phrase that just happened to be the very last line in the presentation for some reason or another.  Could that placement be a signal to us, I thought.

Here's what I found out.  This info is per my memory and to the best of my understanding from an oral conversation:

1.  RESPONSIVENESS:  The company replied to my emailed questions earlier this week within hours, setting expectations with me as to when they would have time to talk.  That time was a few days later this week, as I'm sure they were quite busy this week with the AGM.  I consider this response rate to be very satisfactory.   I'm not sure why other parties think they are not being responsive.   That was not my personal experience at all.

2.  "Commenced" means that new discussions with new parties along those lines (business development, licensing and partnership) have begun RECENTLY.  And to be clear - these dicsussions are with parties not previously at the table.

3.  From the AGM, it has been acknowledged that these discussions are with multiple new parties - at least 3.   I believe this was mentioned there.  I don't know who.  I don't know what.  But it sounds like they meant to tell us that multiple new discussions have recently started.

4.  These discussions are with big pharma.  I believe this was mentioned at the AGM, but I was not there.

5.  The reason for the new discussions is the new data regarding MACE and diabetes melitus.  That new data is apparently very important in terms of the value of our little company.

6.  (From earlier discussions I have had with the company):  This is not post-hoc analysis.  This data is regarding a pre-specified endpoint of the study.  That is part of the value of the new data.

Again - to the best of my memory.

GLTA.  DYODD (Do your own due diligence).









Bullboard Posts